verona
pharma
announces
publication
phase
copd
symptom
data
international
journal
chronic
obstructive
pulmonary
disease
london
raleigh
globe
newswire
verona
pharma
plc
aim
vrp
nasdaq
vrna
verona
pharma
biopharmaceutical
company
focused
respiratory
diseases
announces
publication
detailed
analysis
symptom
data
previously
reported
phase
clinical
trial
nebulized
ensifentrine
maintenance
treatment
chronic
obstructive
pulmonary
disease
copd
leading
peer
reviewed
journal
specialists
healthcare
professionals
international
journal
chronic
obstructive
pulmonary
disease
analyses
demonstrate
ensifentrine
meaningfully
improved
copd
symptoms
weeks
largest
effect
breathlessness
across
two
different
assessment
tools
copd
breathlessness
subscale
transitional
dyspnea
index
tdi
statistically
significant
meaningful
improvements
cough
sputum
chest
symptoms
also
observed
well
improvements
quality
life
measured
paper
entitled
symptom
improvement
following
treatment
inhaled
dual
phosphodiesterase
inhibitor
ensifentrine
patients
moderate
severe
copd
detailed
analysis
available
results
study
first
reported
march
demonstrated
ensifentrine
met
primary
endpoint
producing
clinically
statistically
significant
improvements
lung
function
doses
addition
clinically
relevant
secondary
endpoints
met
including
significant
progressive
improvements
copd
symptoms
information
study
found
ensifentrine
inhaled
dual
inhibitor
enzymes
phosphodiesterase
combines
bronchodilator
activities
one
compound
january
verona
pharma
reported
positive
results
second
phase
study
nebulized
ensifentrine
added
inhaled
tiotropium
therapy
long
acting
lama
bronchodilator
symptomatic
copd
patients
ensifentrine
well
tolerated
clinical
trials
involving
people
date
henrik
watz
pulmonary
research
institute
lung
clinic
grosshansdorf
germany
lead
author
paper
commented
fast
meaningful
effect
ensifentrine
copd
symptoms
particularly
breathlessness
encouraging
relatively
short
study
ensifentrine
activity
may
responsible
impact
symptoms
adds
potential
novel
copd
evaluating
respiratory
symptoms
tdi
transition
dyspnea
index
george
respiratory
questionnaire
recognized
outcome
measures
evaluating
effect
treatments
copd
symptoms
quality
life
use
clinical
studies
copd
information
please
contact
verona
pharma
plc
tel
david
zaccardelli
chief
executive
officer
info
victoria
stewart
director
communications
singer
tel
nominated
adviser
uk
broker
aubrey
powell
george
tzimas
iqra
amin
corporate
finance
tom
salvesen
corporate
broking
optimum
strategic
communications
tel
european
media
investor
enquiries
verona
mary
clark
eva
haas
shabnam
bashir
argot
partners
tel
us
investor
enquiries
verona
kimberly
minarovich
michael
barron
ensifentrine
ensifentrine
investigational
inhaled
dual
inhibitor
enzymes
phosphodiesterase
dual
inhibition
enables
combine
bronchodilator
effects
one
compound
ensifentrine
also
activates
cystic
fibrosis
transmembrane
conductance
regulator
cftr
beneficial
reducing
mucous
viscosity
improving
mucociliary
clearance
ensifentrine
mechanism
action
potential
alleviate
respiratory
symptoms
breathlessness
cough
work
inflammation
triggered
viruses
ensifentrine
demonstrated
significant
clinically
meaningful
improvements
lung
function
symptoms
including
breathlessness
verona
pharma
phase
clinical
studies
patients
moderate
severe
chronic
obstructive
pulmonary
disease
copd
addition
nebulized
ensifentrine
showed
improved
lung
function
reduced
lung
volumes
copd
patients
taking
standard
bronchodilator
therapy
including
maximum
bronchodilator
treatment
dual
triple
therapy
ensifentrine
well
tolerated
clinical
trials
involving
subjects
date
verona
pharma
verona
pharma
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
treatment
respiratory
diseases
significant
unmet
medical
needs
successfully
developed
approved
verona
pharma
product
candidate
ensifentrine
potential
first
therapy
treatment
respiratory
diseases
combines
bronchodilator
activities
one
compound
company
plans
initiate
phase
clinical
program
enhance
ensifentrine
novel
inhaled
nebulized
copd
therapy
later
nebulized
ensifentrine
copd
maintenance
treatment
company
raised
gross
proceeds
million
private
placement
july
expects
funds
support
operations
phase
clinical
program
two
additional
formulations
ensifentrine
currently
phase
development
treatment
copd
dry
powder
inhaler
dpi
pressurized
inhaler
pmdi
ensifentrine
also
potential
applications
cystic
fibrosis
asthma
respiratory
diseases
information
please
visit
statements
press
release
contains
statements
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
limited
development
ensifentrine
progress
timing
initiation
clinical
trials
goals
design
clinical
trials
potential
ensifentrine
phosphodiesterase
inhibitor
first
therapy
treatment
respiratory
diseases
combine
bronchodilator
effects
one
compound
potential
ensifentrine
alleviate
copd
symptoms
breathlessness
cough
work
inflammation
ability
company
progress
development
ensifentrine
secure
supplies
drug
ongoing
development
commercialization
sufficiency
funds
supports
operations
phase
clinical
program
potential
ensifentrine
treatment
copd
cystic
fibrosis
asthma
respiratory
diseases
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
expectations
expressed
implied
statements
including
limited
following
limited
operating
history
need
additional
funding
complete
development
commercialization
ensifentrine
may
available
may
force
us
delay
reduce
eliminate
development
commercialization
efforts
reliance
business
success
ensifentrine
product
candidate
development
economic
political
regulatory
risks
involved
international
operations
lengthy
expensive
process
clinical
drug
development
uncertain
outcome
serious
adverse
undesirable
unacceptable
side
effects
associated
ensifentrine
could
adversely
affect
ability
develop
commercialize
ensifentrine
potential
delays
enrolling
patients
could
adversely
affect
research
development
efforts
completion
clinical
trials
may
successful
developing
ensifentrine
multiple
indications
ability
obtain
approval
commercialize
ensifentrine
multiple
major
pharmaceutical
markets
misconduct
improper
activities
employees
consultants
principal
investigators
service
providers
future
growth
ability
compete
depends
retaining
key
personnel
recruiting
additional
qualified
personnel
material
differences
data
final
data
reliance
third
parties
including
clinical
research
organizations
clinical
investigators
manufacturers
suppliers
risks
related
parties
ability
successfully
develop
commercialize
ensifentrine
lawsuits
related
patents
covering
ensifentrine
potential
patents
found
invalid
unenforceable
vulnerability
natural
disasters
global
economic
factors
unexpected
events
including
health
epidemics
pandemics
like
novel
coronavirus
important
factors
caption
risk
factors
annual
report
form
filed
securities
exchange
commission
sec
february
caption
supplemental
risk
factor
disclosures
report
form
filed
sec
april
caption
risk
factors
registration
statement
form
filed
sec
august
reports
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
